LEADER 03914nam 22006495 450 001 9910300238903321 005 20200703024402.0 010 $a3-319-15750-7 024 7 $a10.1007/978-3-319-15750-4 035 $a(CKB)3710000000414144 035 $a(EBL)2094441 035 $a(SSID)ssj0001501645 035 $a(PQKBManifestationID)11901926 035 $a(PQKBTitleCode)TC0001501645 035 $a(PQKBWorkID)11446923 035 $a(PQKB)10280947 035 $a(DE-He213)978-3-319-15750-4 035 $a(MiAaPQ)EBC2094441 035 $a(PPN)186025882 035 $a(EXLCZ)993710000000414144 100 $a20150512d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aOptimizing Treatment for Children in the Developing World /$fedited by Stuart MacLeod, Suzanne Hill, Gideon Koren, Anders Rane 205 $a1st ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Adis,$d2015. 215 $a1 online resource (333 p.) 300 $aDescription based upon print version of record. 311 $a3-319-15749-3 327 $aForeword -- Shifting demographics and regional disparities -- Access issues -- Ending stockouts -- Improved formulations and optimal dosing -- Deficient and counterfeit products -- Knowledge gaps in pregnancy and lactation -- Factors enabling improved therapy -- Regulatory science -- Human resource planning -- Information and communications technology -- Pharmaceutical care -- Networks (GRIP, INRUD, MSH, PTN,MYCRN, IABMC) -- Research challenges -- Research standards for clinical trials in low and middle income countries -- Innovative appropriate trial methods -- Nutrition/micronutrients -- Impact on therapeutic outcomes -- Drug safety and pharmaco-epidemiology -- Personalized treatment and Pharmacogenomics -- Neglected diseases -- Health outcomes and economics -- Enhanced industry engagement -- Incorporating social science perspectives -- Clinical settings -- Treatment in the community -- Treatment at the district hospital level -- Care of the critically ill child -- Palliative care and pain management. ? Conclusion -- The light at the end of the tunnel: future directions. 330 $aThis book is intended to communicate current best practice in pediatric clinical pharmacology and clinical pharmacy with special consideration of the prevailing circumstances and most pressing needs in developing countries. It also addresses measures that may be taken in countries with emerging economies through organizational and political adjustments to reduce unacceptable levels of morbidity and mortality among children and pregnant women with treatable diseases. 606 $aPediatrics 606 $aGeneral practice (Medicine) 606 $aPharmacotherapy 606 $aPediatrics$3https://scigraph.springernature.com/ontologies/product-market-codes/H49006 606 $aGeneral Practice / Family Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H24003 606 $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000 615 0$aPediatrics. 615 0$aGeneral practice (Medicine). 615 0$aPharmacotherapy. 615 14$aPediatrics. 615 24$aGeneral Practice / Family Medicine. 615 24$aPharmacotherapy. 676 $a610 676 $a615.1 676 $a618.92 702 $aMacLeod$b Stuart$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aHill$b Suzanne$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aKoren$b Gideon$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aRane$b Anders$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300238903321 996 $aOptimizing Treatment for Children in the Developing World$91864502 997 $aUNINA